NASDAQ · CABA
Healthcare · Biotechnology
$2.08
Down-$0.08 (-3.85%)
Updated Oct 6, 2026, 7:42 PM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CABA
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
CABA closed at $2.08 after 20 trading sessions, down 36.39% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $2.01 | $2.12 | $1.955 | $2.08 | 5.41M |
| Oct 2, 2026 | $1.94 | $2.01 | $1.83 | $2.00 | 5.71M |
| Oct 1, 2026 | $1.92 | $1.97 | $1.86 | $1.89 | 8.54M |
| Sep 30, 2026 | $2.01 | $2.01 | $1.90 | $1.92 | 8.05M |
| Sep 29, 2026 | $2.01 | $2.03 | $1.95 | $1.98 | 4.19M |
| Sep 28, 2026 | $2.06 | $2.07 | $1.98 | $2.00 | 5.44M |
| Sep 25, 2026 | $2.17 | $2.17 | $2.05 | $2.07 | 3.1M |
| Sep 24, 2026 | $2.23 | $2.23 | $2.06 | $2.155 | 5.59M |
| Sep 23, 2026 | $2.53 | $2.56 | $2.19 | $2.22 | 8.68M |
| Sep 22, 2026 | $2.48 | $2.60 | $2.46 | $2.50 | 5.31M |
| Sep 21, 2026 | $2.64 | $2.65 | $2.45 | $2.46 | 4.73M |
| Sep 18, 2026 | $2.55 | $2.61 | $2.52 | $2.55 | 12.48M |
| Sep 17, 2026 | $2.52 | $2.59 | $2.50 | $2.58 | 4.26M |
| Sep 16, 2026 | $2.65 | $2.68 | $2.48 | $2.49 | 6.14M |
| Sep 15, 2026 | $2.89 | $2.92 | $2.57 | $2.595 | 7.24M |
| Sep 14, 2026 | $2.72 | $3.04 | $2.71 | $2.91 | 6.31M |
| Sep 11, 2026 | $2.77 | $2.886 | $2.67 | $2.73 | 7.44M |
| Sep 10, 2026 | $2.85 | $2.875 | $2.69 | $2.74 | 7.08M |
| Sep 9, 2026 | $3.28 | $3.28 | $2.90 | $2.91 | 6.51M |
| Sep 8, 2026 | $3.43 | $3.48 | $3.26 | $3.27 | 3.07M |
The latest Smart Investors Daily articles mentioning CABA.
Company
Market Activity
Research & News
CABA research
Company profile and research snapshot.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 1, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2026 | Wells Fargo | Equal-Weight | — |
| May 15, 2026 | Wells Fargo | Equal-Weight | — |
| May 4, 2026 | Cantor Fitzgerald | Overweight | — |
| Mar 24, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
Yahoo · Mar 7, 2026
Cabaletta Bio (NASDAQ:CABA) used a fireside chat at TD Cowen’s 46th Annual Health Care Conference to highlight progress across its autoimmune cell therapy program, with executives emphasizing upcoming clinical readouts, a push toward non-preconditioning regimens, and a manufacturing strategy built a
Yahoo · Mar 6, 2026
Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Yahoo · Mar 3, 2026
Here is how Biodesix, Inc. (BDSX) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Yahoo · Feb 24, 2026
PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 11:10 a.m. ET in Boston, MA. A live webcast of the presentation will be available
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CABA.
